Physician profile
Ira Bell
NPI 1336114545
$8,784.51
in general payments reported to CMS, 2019-2025
35 companies · $1,433 in 2025
The $1,433 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,262 · 2020: $419 · 2021: $1,030 · 2022: $1,323 · 2023: $1,696 · 2024: $1,620 · 2025: $1,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,558 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,558.41 |
| Education | $191.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,939.81 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Regeneron Healthcare Solutions, INC. | $880.20 | 2019-2025 | Libtayo, Dupixent |
| Pfizer INC. | $821.58 | 2019-2025 | |
| Incyte Corporation | $679.27 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $525.72 | 2019-2025 | |
| Janssen Biotech, INC. | $493.55 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Leo Pharma INC. | $469.29 | 2019-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $447.50 | 2022-2024 | Sotyktu |
| Amgen INC. | $398.39 | 2021-2024 | Otezla |
| Allergan, INC. | $352.27 | 2019-2021 | |
| Genzyme Corporation | $321.67 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $287.31 | 2019-2025 | Ilumya |
| Lilly USA, LLC | $238.27 | 2019-2025 | Ebglyss, Taltz |
| Galderma Laboratories, L.P. | $159.81 | 2020-2025 | Nemluvio |
| Ucb, INC. | $136.55 | 2021-2025 | Bimzelx, Cimzia |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Strata Skin Sciences, INC. | $104.31 | 2019-2025 | Xtrac |
| Sanofi-Aventis U.S. LLC | $71.59 | 2021 | |
| Journey Medical Corporation | $60.84 | 2019-2023 | |
| Almirall LLC | $41.83 | 2025 | Klisyri |
| Organon LLC | $30.00 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $28.87 | 2020-2021 | |
| Celgene Corporation | $28.56 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.09 | 2022-2023 | Spevigo |
| Mayne Pharma Commercial LLC | $24.43 | 2019 | |
| Revance Therapeutics, INC. | $24.11 | 2025 | Daxxify |
| Verrica Pharmaceuticals INC. | $24.04 | 2024 | Ycanth |
| Lnhc, INC | $23.89 | 2025 | Zelsuvmi |
| Arcutis Biotherapeutics, INC. | $22.52 | 2025 | Zoryve |
| Misonix INC | $20.76 | 2021 | |
| Solta Medical, A Division of Bausch Health US, LLC | $20.44 | 2025 | |
| Vyne Pharmaceuticals INC. | $19.61 | 2020 | |
| Botanix Sb INC | $17.12 | 2025 | Sofdra |
| Biofrontera INC. | $17.02 | 2019 | |
| Bioventus LLC | $13.85 | 2022 | |
| Icad, INC | $12.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ira Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.